Thymus Nuclear Protein is the core of our initial approach to the development of immune-based therapies. Our lead product candidate is VGV-1, an investigational treatment for HIV/AIDS, consists of thymus nuclear protein (TNP) suspended in adjuvant.

TNP proteins were originally studied as a means of early-detection of certain cancers. In a series of early pilot studies, it was learned that if the protein was introduced to an HIV-positive patient’s system along with adjuvant, over time an immuno-precipitation reaction gradually reappeared over approximately 8 weeks that was similar to an HIV-negative patient’s reaction. This was the genesis of understanding the therapeutic potential of TNP and led directly to our clinical development of VGV-1.

We recently licensed technology developed by Dr. Karen Newell at the University of Colorado. The technology appears to identify the active components of TNP, and may explain the mechanism of action behind the reductions in viral load we have seen in our studies of HIV/AIDS patients. We are now completing studies aimed at confirming the connection between Dr. Newell’s work and TNP.

To learn more about VGV-1, click here.

To learn more about our clinical trials, click here.

Discovery

Our Vision

Immune-Based Therapies

Immune-Based Therapies FAQ

Click here for a stock quote.

VRAL:OB